6 176

Cited 8 times in

Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis.

Authors
Chung, HY; Chin, SO; Kang, MI; Koh, JM; Moon, SH; Yoon, BK; Yoon, HK; Chung, YS; Park, HM
Citation
Clinical endocrinology, 74(6):699-704, 2011
Journal Title
Clinical endocrinology
ISSN
0300-06641365-2265
Abstract
BACKGROUND: We performed a randomized, double-blind, prospective, 16-week clinical trial to evaluate the efficacy and safety of risedronate with and without cholecalciferol on 25-hydroxyvitamin D [25(OH)D] levels and bone markers in Korean patients with osteoporosis.



METHODS: We randomly assigned 164 adults with osteoporosis to one of two treatment groups: weekly risedronate 35 mg and cholecalciferol 5600 IU combined in a single pill (RSD+) or weekly risedronate 35 mg alone (RSD). We measured serum levels of 25(OH)D, parathyroid hormone (PTH), and bone markers and performed muscle function tests, at baseline and after 16 weeks of treatment.



RESULTS: After 16 weeks of treatment, mean serum 25(OH)D increased significantly from 39·8 to 70·8 nmol/l in the RSD+ group and declined significantly from 40·5 to 35 nmol/l in the RSD group. Although both treatment groups had significant increases in serum PTH over baseline during the study, the RSD group had a significantly larger increase than the RSD+ group (13·6 vs 4·8 ng/l; P = 0·0005). In both groups, serum bone-specific alkaline phosphatase (BSAP) and C-terminal telopeptide (CTX) declined rapidly; there were no significant differences between groups. There was also no significant difference between groups in lower-extremity function tests. The overall incidence of clinical adverse events was not significantly different between groups.



CONCLUSION: In patients with osteoporosis, a once-weekly pill of risedronate and cholecalciferol provided equivalent antiresorptive efficacy to risedronate alone in terms of bone turnover and improved 25(OH)D level over a 16-week treatment period without significant adverse events.
MeSH terms
AgedAlkaline Phosphatase/bloodAsian Continental Ancestry GroupBone Density/*drug effectsBone Density Conservation Agents/adverse effects/therapeutic useCholecalciferol/adverse effects/*therapeutic useCollagen Type I/bloodDouble-Blind MethodDrug Therapy, CombinationEtidronic Acid/adverse effects/*analogs & derivatives/therapeutic useFemaleGastrointestinal Diseases/chemically inducedHumansKoreaMaleMiddle AgedOsteoporosis/blood/*drug therapy/ethnologyOsteoporosis, Postmenopausal/blood/drug therapy/ethnologyParathyroid Hormone/bloodPeptides/bloodProspective StudiesRadioimmunoassayTreatment OutcomeVitamin D/*analogs & derivatives/blood
DOI
10.1111/j.1365-2265.2011.04041.x
PMID
21521310
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Endocrinology & Metabolism
AJOU Authors
정, 윤석
Full Text Link
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse